A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Keratoconjunctivitis Sicca Clinical Trial

Official title:

Phase 2, Single-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophth Sol'n in the Environment and During Challenge in the Controlled Adverse Environment (CAE) Model for the Treatment of DES

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02121301
• Other study ID #: 13-110-0006
• Status: Completed
• Phase: Phase 2
• Start date: April 2014
• Est. completion date: June 2014

Study information

• Verified date: October 2020
• Source: Mitotech, SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

Description:

Single-center, double-masked, randomized, placebo-controlled study comprising 4 visits over the course of approximately 5 weeks. The study included a 1-week placebo (SkQ1 vehicle) run-in period between Visit 1 and Visit 2, and approximately 28 days of twice daily (BID) dosing (Visit 2 - Visit 4). Qualified subjects were randomized 1:1:1 to receive either 1.55 µg/mL SkQ1 ophthalmic solution, 0.155 µg/mL SkQ1 ophthalmic solution, or placebo (vehicle of SkQ1 ophthalmic solution).

The following primary endpoints were tested:

• Corneal Fluorescein staining in the inferior region Pre-CAE at Visit 4 (Day 29), as measured by the Ora Calibra Scale in the worst eye at baseline;

• Worst dry eye symptom (ocular discomfort, dryness, or grittiness - as determined from subject diary data recorded during the 1-week run-in period between Visit 1 and Visit 2) evaluated over the seven days preceding Visit 4 (not including day of visit) during the treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 91
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be male or female of any race, at least 18 years of age

• Have provided written informed consent

• Have a reported history of dry eye syndrome

• Have a history of use or desire to use eye drops for dry eye

Exclusion Criteria:

• Have any clinically significant eye findings that require therapeutic treatment or may interfere with study parameters

• Have previously had LASIK surgery within the last 12 months

• Have used Restasis® within 30 days of Visit 1

• Be a woman who is pregnant, nursing or planning a pregnancy

• Be unwilling to submit a urine pregnancy test if of childbearing potential

• Have a known allergy and/or sensitivity to the test article or its components, including the preservative benzalkonium chloride

• Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1

• Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Related Conditions & MeSH terms

• Dry Eye Syndromes
• Keratoconjunctivitis
• Keratoconjunctivitis Sicca

Intervention

Drug:
• Low Dose 0.155µg/mL SkQ1 ophthalmic solution
eyedrops
• High Dose 1.55µg/mL SkQ1 ophthalmic solution
eyedrops
• Placebo (Vehicle) opthalmic solution
eyedrops

Locations

Country	Name	City	State
United States	Lawrence General Hospital	Andover	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Mitotech, SA	ORA, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Inferior Corneal Fluorescein Staining	The dry eye sign primary efficacy variable of corneal fluorescein staining of the inferior region of the eye measured on a 0-4 point scale where 0 = no staining and 4 = most staining between treatment arms at day 29	Day 29
Primary	Worst Symptom Based on Diary Data	Worst dry eye symptom (as determined from subject diary data recorded during the 1-week run-in period) evaluated over the seven days preceding Day 29 during the treatment period. The scale was on a 0-5 range where 0= no symptoms and 5= worst symptoms measured for a number of dry eye symptoms.	Day 29